Sodexo Unveils Shift & Grow 2030 Strategy, Targets Over 5% Revenue Growth by Fiscal 2030 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
VANCOUVER, British Columbia, Jan. 27, 2016 -- AbCellera, a biotechnology company specializing in the rapid discovery of monoclonal antibodies from natural immune cells, today announced a new collaboration with Merck, known as MSD outside the United States and Canada, through a subsidiary, to generate antibodies against an undisclosed disease target.
“Our platform has the potential to generate functional antibodies against extremely difficult targets that have been intractable until now,” says Dr. Carl Hansen, President and CEO of AbCellera. “We’re excited to partner with a global innovator like Merck in the discovery of antibodies to advance their pipeline of next-generation therapies.”
“Merck recognizes the innovative science and synergy of collaboration in British Columbia. Our company has established several life sciences collaborations in the province aimed at translating breakthrough science into products that can bring meaningful improvements to patients' lives,” explained Chirfi Guindo, President and Managing Director at Merck Canada Inc. “We are pleased to be working with AbCellera to identify novel antibodies using their innovative microfluidic discovery technology.”
Under the agreement, AbCellera will apply its high-throughput antibody discovery platform to identify antibodies that specifically modulate target function. The agreement grants Merck the option to develop antibody candidates identified through the collaboration for specified therapeutic applications. Financial terms of the deal were not disclosed.
About AbCellera Biologics Inc.
AbCellera is a privately held biotechnology company that provides enabling technologies for the discovery and development of monoclonal antibody (mAb) therapies directly from natural immune cells.
AbCellera’s lead technology is a proprietary single cell antibody discovery platform that provides pharma and biotech partners with the ability to rapidly identify mAb therapeutic candidates from the natural immune repertoires of any species, including humans. For more information, please visit www.abcellera.com
Contact Kevin Heyries Telephone: 604.827.4151 Email: [email protected]
